uniQure (QURE) Q2 2026 Earnings Call Transcript
uniQure (NASDAQ:QURE) reported Q2 2026 results and said the FDA aligned on submitting a Huntington’s disease AMT-130 BLA under accelerated approval in Q3 2026 using three-year data. Cash and investments were $810.3M at June 30, 2026 after a $259M follow-on. Q2 revenue was $5.8M, net loss $81.1M.
How this was made
The 30-second read
Why it matters
The most tradable new information is FDA alignment for an AMT-130 accelerated-approval BLA submission in Q3 2026, including confirmatory study design and endpoint framing. The call also updates capital runway and highlights ongoing clinical risk in AMT-191 due to liver enzyme elevations and a dosing pause.
Market read
Traders can update uniQure’s probability-weighted regulatory timeline for AMT-130 based on FDA alignment and the planned Q3 2026 BLA filing, while monitoring AMT-191 safety and confirmatory study enrollment progress.
What to watch
AMT-191 remains paused in mid- and high-dose cohorts due to Grade 3 liver enzyme elevations, and AMT-260 enrollment timing could slip, both of which can offset optimism from AMT-130 regulatory progress.
Background
This is uniQure’s Q2 2026 earnings call transcript covering cash position, regulatory alignment for AMT-130, and clinical/program updates across AMT-130, AMT-260, and AMT-191.
Ticker impact
uniQure says it reached FDA alignment to submit an AMT-130 BLA under accelerated approval in Q3 2026 using three-year data.
Likely positive bias for QURE into the Q3 2026 BLA window, with volatility around confirmatory study enrollment and AMT-191 safety updates.
The article provides specific FDA alignment details (accelerated approval pathway, confirmatory design, primary endpoint) plus cash runway into 2030, which together improve execution visibility. Offsetting risk comes from the AMT-191 dosing pause due to Grade 3 liver enzyme elevations.
Market effects
Reinforces investor focus on gene-therapy regulatory pathways (accelerated approval plus confirmatory study design) and the importance of endpoint acceptability.
UK/EU regulatory progress (MHRA MAA on track for Q3 2026, EMA engagement planned for 2027) supports broader European sentiment for gene-therapy developers.
FDA alignment details may influence read-across expectations for other neurodegeneration gene-therapy programs using intermediate endpoints.
Counterpoint
The FDA alignment is pathway and design alignment, not approval; confirmatory enrollment and endpoint validation remain major execution risks that can still delay or weaken the accelerated approval outcome.
Key entities
- companyuniQure N.V.
NASDAQ-listed gene therapy developer reporting Q2 2026 results and FDA alignment for AMT-130 accelerated approval BLA submission.
- programAMT-130
Investigational gene therapy for Huntington’s disease; FDA alignment for Q3 2026 BLA submission under accelerated approval.
- regulatorFDA
Aligned with uniQure on accelerated approval BLA submission timing and confirmatory study design for AMT-130.
- programAMT-191
Investigational gene therapy for Fabry disease; dosing paused in mid- and high-dose cohorts after Grade 3 liver enzyme elevations.
- regulatorMHRA
UK regulator; MAA submission for AMT-130 on track for Q3 2026.
